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Identification of Regions Important for Resistance and Signalling
within the Antimicrobial Peptide Transporter BceAB of Bacillus
subtilis
Felix Kallenberg, Sebastian Dintner, Roland Schmitz, Susanne Gebhard
Ludwig-Maximilians-Universität München, Department Biology I, Microbiology, Martinsried, Germany
In the low-GC-content Gram-positive bacteria, resistance to antimicrobial peptides is often mediated by so-called resistance
modules. These consist of a two-component system and an ATP-binding cassette transporter and are characterized by an un-
usual mode of signal transduction where the transporter acts as a sensor of antimicrobial peptides, because the histidine kinase
alone cannot detect the substrates directly. Thus, the transporters fulfill a dual function as sensors and detoxification systems to
confer resistance, but the mechanistic details of these processes are unknown. The paradigm and best-understood example for
this is the BceRS-BceABmodule of Bacillus subtilis, which mediates resistance to bacitracin, mersacidin, and actagardine. Using
a randommutagenesis approach, we here show that mutations that affect specific functions of the transporter BceAB are primar-
ily found in the C-terminal region of the permease, BceB, particularly in the eighth transmembrane helix. Further, we show that
while signaling and resistance are functionally interconnected, several mutations could be identified that strongly affected one
activity of the transporter but had only minor effects on the other. Thus, a partial genetic separation of the two properties could
be achieved by single amino acid replacements, providing first insights into the signaling mechanism of these unusual modules.
Many bacteria produce antibiotics to gain a competitive ad-vantage over other microorganisms inhabiting the same
ecological niche. Among the low-GC-content Gram-positive
bacteria, the Firmicutes, production of antimicrobial peptides is
widely distributed. These compounds generally act by an inhibi-
tion of the lipid II cycle of cell wall synthesis (1, 2). For example,
lantibiotics such as nisin or mersacidin bind to lipid II directly
(1–3), whereas the non-ribosomally synthesized bacitracin pre-
vents the dephosphorylation and recycling of the lipid carrier un-
decaprenyl-pyrophosphate (4). For self-protection, producer
strains of antimicrobial peptides express so-called immunity pro-
teins, summarily referred to as LanI, as well as ATP-binding cas-
sette (ABC) transporters of the LanFEG or BcrAB type (5–8).
In order to compete successfully with such strains, nonproduc-
ing Firmicutes bacteria have also developed resistance mecha-
nisms, the most efficient of which are again ABC transporters.
However, these transporters differ in sequence and domain archi-
tecture from those of the producer strains and are collectively
referred to as BceAB-type transporters (8, 9). They consist of an
ATPase (BceA) and a permease (BceB) with 10 transmembrane
helices and a characteristic, large extracellular domain of approx-
imately 200 amino acids between helices VII and VIII. The epon-
ymous and best-characterized example is BceAB of Bacillus subti-
lis, which confers resistance to bacitracin, mersacidin, and
actagardine (10, 11). BceAB-type transporters are found in a con-
served genomic arrangement with two-component systems (re-
ferred to as BceRS-like) whose histidine kinases possess two trans-
membrane helices but lack any extracellular sensory domains (9,
12, 13). Together, the transporter and the two-component system
constitute peptide antibiotic resistance modules. Their most strik-
ing property is the unusual mode of signal transduction: the his-
tidine kinases alone cannot detect the presence of antimicrobial
peptides but instead rely on the transporters for stimulus percep-
tion. In the presence of a substrate peptide, the transporter some-
how communicates with the sensor kinase, which leads to activa-
tion of the cognate response regulator and, subsequently, an
induction of transporter gene expression. Importantly, ATP hy-
drolysis by the transporter and therefore active transport are re-
quired for the signaling process (10, 14). Experimental evidence
from a number of homologous systems from B. subtilis, Staphylo-
coccus aureus, Streptococcus mutans, and Lactobacillus casei con-
firms this signaling pathway as a general characteristic of the Bce-
type modules (10, 11, 14–17). Based on the coevolution of the
proteins involved and supported by bacterial two-hybrid analyses
of the VraFG transporter and GraRS two-component system of S.
aureus, it is thought that communication within these modules
involves direct protein-protein contacts between the transporter
and histidine kinase (9, 15, 18). However, no information is avail-
able regarding the mechanism of signaling.
In this study, we performed a random mutagenesis of the
transport permease BceB of B. subtilis with the aim to identify
regions or residues within the transporter that are involved in
signaling and/or resistance. A central question was whether amino
acid replacements could be identified that affected only one but
not the other function of BceB. In other words, are the two traits
genetically separable in a dual-function transporter such as
BceAB? We show that a partial separation of signaling and resis-
tance could be obtained from single point mutations and further
identify the C-terminal region of the transport permease as func-
tionally important.
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MATERIALS AND METHODS
Bacterial strains and growth conditions. B. subtilis and Escherichia coli
were routinely grown in Luria-Bertani (LB) medium at 37°C with agita-
tion (200 rpm). During cloning of bacterial two-hybrid constructs, all
media for E. coli were supplemented with 0.4% (wt/vol) glucose. Trans-
formations of B. subtilis were carried out as described previously (19). All
strains used in this study are listed in Table 1. Selective media contained
kanamycin (10 g ml1 for B. subtilis, 50 g ml1 for E. coli), spectino-
mycin (100 g ml1), chloramphenicol (5 g ml1), or ampicillin (100
g ml1). Solid media contained 1.5% (wt/vol) agar.
Plasmid construction. All plasmids created during this study are
listed in Table 1; all primer sequences are given in Table 2. Only plasmids
and derived strains harboring constructs with the wild-type sequence of
bceB are listed; all other strains are referred to as their wild-type counter-
parts, with the amino acid exchange given in parentheses.
To create a plasmid for xylose-inducible expression of bceAB in B.
subtilis (pSG704), a 2.8-kb fragment containing the entire operon, includ-
ing the ribosome binding site, was PCR amplified using primers 0011 and
1524. The resulting product was cloned as a BamHI fragment into vector
pXT (23), placing the genes under the control of the vector’s xylA pro-
moter. A similar construct expressing bceAB with a triple FLAG tag fused
to the C terminus of BceB (pFK727) was created using primers 0011 and
1706 followed by cloning into the BamHI site of pXT.
To create a transcriptional fusion of the bceA promoter, PbceA, to a
promoterless luciferase operon (luxABCDE), a 207-bp fragment encom-
passing the promoter region from 127 bp upstream to 80 bp downstream
of the bceA start codon was PCR amplified with primers 0554 and 2241.
The resulting product was cloned into the EcoRI and NotI sites of vector
pAH328 (21), creating plasmid pSDlux101.
For bacterial two-hybrid analyses (22), a 1.2-kb DNA fragment con-
taining bceS was amplified via PCR using primers 1355 and 1356 and
cloned into the XbaI and KpnI restriction sites of vector pUT18, resulting
in a translational fusion of the T18 fragment ofBordetella pertussisCyaA to
the C terminus of BceS (pAS1803). The same strategy was used to create a
translational fusion of the T18 fragment to the C terminus of BceA in
pAS1804 (760-bp fragment amplified with primers 1357 and 1358). Fur-
thermore, a 1.9-kb fragment containing bceBwas amplified using primers
1359 and 1360 and cloned via the XbaI and KpnI sites into vector pKT25,
resulting in a translational fusion of the CyaA T25 fragment to the N
terminus of BceB (pAS2505).
Random chemical mutagenesis. To generate random mutations in
bceB, 10g of plasmid DNA of pER703 (10) was mixed with 10 vol of HA
solution (1 M hydroxylamine hydrochloride, 100 mM NaCl, 50 mM so-
dium phosphate [pH 6], 2 mM EDTA [pH 8]) and incubated at 75°C for
15 min followed by purification with a HighYield PCR-clean up kit (Süd-
Laborbedarf, Gauting, Germany). Mutagenized plasmid DNA was then
linearized with ScaI, and 2 g of this was used to transform B. subtilis
strain TMB301 with selection for resistance to kanamycin and spectino-
mycin. The resulting transformants were replica stamped with velvet pads
onto indicator plates containing xylose (0.2% [wt/vol]), 5-bromo-4-
chloro-3-indolyl--D-galactopyranoside (X-Gal) (200 g ml1), and
Zn2-bacitracin (Sigma; 0.5 g ml1). All white colonies were again rep-
lica plated onto indicator plates and selective media (kanamycin, specti-
nomycin, chloramphenicol) to confirm the phenotype. Positive clones
(i.e., those showing white colonies and resistance to all antibiotics) were
then tested for threonine auxotrophy to confirm correct integration of the
pXT construct into thrC. For this, each clone was inoculated into MNGE
medium [100 mM glucose, 80 mM K2HPO4, 45 mM KH2PO4, 10 mM
potassium glutamate, 4 mM sodium acetate, 3 mM MgSO4, 50 g ml
1
tryptophan, and 40 M Fe(III)-ammonium citrate], with and without
TABLE 1 Plasmids and strains used in this study
Plasmid or
strain Descriptiona
Reference or
source
Plasmids
pAC6 Vector for transcriptional promoter fusions to lacZ; integrates at amyE; Cmr 20
pAH328 Vector for transcriptional promoter fusions to luxABCDE (luciferase); integrates in sacA; Cmr 21
pKT25 Translational fusion of cyaA T25 fragment to N terminus of insert polypeptide; lac promoter; Kanr 22
pUT18 Translational fusion of cyaA T18 fragment to C terminus of insert polypeptide; lac promoter; Ampr 22
pXT Vector for xylose-inducible gene expression; integrates in thrC; Spcr 23
pAS1803 pUT18-bceS This study
pAS1804 pUT18-bceA This study
pAS2505 pKT25-bceB This study
pER603 pAC6-PbceA-lacZ 10
pER703 pXT-bceB 10
pFK727 pXT-bceAB-FLAG3 This study
pSDlux101 pAH328-PbceA-luxABCDE This study
pSG704 pXT-bceAB This study
E. coli strains
XL1-Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F=::Tn10 proAB lacIq (lacZ)M15] Stratagene
BTH101 F cya-99 araD139 galE15 galK16 rpsL1 hsdR2 mcrA1 mcrB1 Euromedex
B. subtilis strains
W168 Wild type, trpC2 Laboratory stock
SGB079 W168 bceAB::Kan sacA::pSDlux101 This study
SGB082 W168 bceAB::Kan sacA::pSDlux101 thrC::pSG704 This study
SGB170 W168 bceAB::Kan thrC::pSG704 This study
SGB176 W168 bceAB::Kan thrC::pFK727 This study
TMB035 W168 bceAB::Kan 10
TMB301 W168 bceB::Kan amyE::pER603 10
TMB378 W168 bceB::Kan amyE::pER603 thrC::pER703 10
a Only constructs with WT sequence inserts and derived strains are listed; mutated constructs and strains are named according to their amino acid exchanges throughout the article.
Ampr, ampicillin resistance; Cmr, chloramphenicol resistance; Kanr, kanamycin resistance; Spcr, spectinomycin resistance.
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addition of 50 g ml1 threonine. From each clone that was unable to
grow in the absence of threonine, the introduced bceB gene was reampli-
fied by colony PCR using pXT-specific primers, and the resulting product
was sequenced to identify any introduced mutations.
Site-directed mutagenesis. For characterization of the mutations,
each amino acid exchange identified by the random mutagenesis ap-
proach was reconstructed by site-directed mutagenesis of pSG704. Se-
lected amino acid exchanges were also introduced into pFK727 and
pAS2505. Primer design and mutagenesis were performed according to
the manufacturer’s instructions for the QuikChange II site-directed mu-
tagenesis kit (Agilent Technologies). Where this procedure was not suc-
cessful, mutations were introduced using the PCR-overlap extension
method (24), followed by cloning into the desired vector as described for
plasmid construction above. All plasmids were sequenced to confirm in-
troduction of the desired mutation.
Reporter gene assays. Luciferase activities of strains harboring
pSDlux101 were assayed using a Synergy2 multimode microplate reader
from BioTek. The reader was controlled using the software Gen5. LB
medium was inoculated at 1:1,000 from overnight cultures of reporter
strains, and each strain was grown in a 100-l volume in four wells of a
96-well plate. Cultures were incubated at 37°C with agitation (intensity,
medium) and the optical density at 600 nm (OD600) was monitored every
10 min. At an OD600 of 0.02 (4 to 5 population doublings since inocula-
tion, corresponding to an OD600 of 0.1 in cuvettes of 1-cm-light-path
length), Zn2-bacitracin was added to final concentrations of 3, 10, or 30
g ml1, with one well left uninduced. Cultures were further incubated
for 1 h, and the OD600 and luminescence (end point reads; 1-s integration
time; sensitivity, 200) were monitored every 5 min. OD600 values were
corrected using wells containing 100 l LB medium as blanks. Raw lumi-
nescence output (measured in relative luminescence units [RLU]) was
normalized to cell density by dividing each data point by its correspond-
ing corrected OD600 value (RLU/OD).
Bacitracin sensitivity assays. The sensitivity of B. subtilis strains to
bacitracin was determined as the MIC. For this, serial 2-fold dilutions of
Zn2-bacitracin from 32g ml1 to 2g ml1 were prepared in Mueller-
Hinton medium containing 0.2% (wt/vol) xylose. As a control, Mueller-
Hinton medium without bacitracin was used. For each concentration, 2
ml of media were inoculated at 1:500 from overnight cultures grown in
Mueller-Hinton medium with xylose and selective antibiotics. Each cul-
ture was scored for growth after 20 to 24 h of incubation at 37°C with
agitation. The MIC was determined as the lowest bacitracin concentration
where no growth was detected.
Western blot analyses. To compare production levels of BceB and its
derivatives in membranes of B. subtilis, strain SGB176 carrying plasmid
TABLE 2 Primers used in this study
Primer name Sequence (5=–3=)
Oligonucleotides for
cloninga
0011 GAATGGATCCGATTATCCAATATAAAGGAGACTGCG
0554 GATCGAATTCGAACATGTCATAAGCGTGTGACG
1355 GTCATCTAGAGATGATTAAAGCATTCCTTATCG
1356 GTCAGGTACCTGCACGCTTATGACATGTTC
1357 GTCATCTAGAGATGGTGATTTTAGAAGCG
1358 GTCAGGTACCTGATGTTCATGCTGCACC
1359 GTCATCTAGAGATGAACATTAATCAGCTCATCC
1360 GTCAGGTACCTGCAACGACGATTTAATGACC
1524 AATTGGATCCTTTTCTGTTTCACAACGACG
1706 TTAAGGATCCTCACTTGTCGTCATCGTCTTTGTAGTCGATA
TCATGATCCTTATAATCACCATCATGATCCTTATAAT
CCAACGACGATTTAATGACC
2241 AATTGCGGCCGCTATCGATGCCCTTCAGCACTTCC
Oligonucleotides for
site-directed
mutagenesisb
R9Q-fwd CATTAATCAGCTCATCCTGCAAAATTTGAAAAAGAATCT
CCGG
R9Q-rev CCGGAGATTCTTTTTCAAATTTTGCAGGATGAGCTGATT
AATG
V22 M-fwd CCGGAATTACTATTTGTATATGTTTGCGCTCATCTTTAGCG
V22 M-rev CGCTAAAGATGAGCGCAAACATATACAAATAGTAATTCCGG
A75T-fwd GTGGCTGTAGTGGCGATCTTCATTTTATATACCAATACGA
TTTTT
A75T-rev AAAAATCGTATTGGTATATAAAATGAAGATCGCCACTACA
GCCAC
R83W-fwd CAATACGATTTTTATTAAGAGATGGAGTAAAGAAATCGG
GCTG
R83W-rev CAGCCCGATTTCTTTACTCCATCTCTTAATAAAAATCGT
ATTG
A117T-fwd GTATTTCGGTTCATTAACGATCGGGGTAGCGGC
A117T-rev GCCGCTACCCCGATCGTTAATGAACCGAAATAC
V130I-fwd CGGGTTTTCGATATCGAAGCTTATCTTGATGATTCTGTTC
V130I-rev GAACAGAATCATCAAGATAAGCTTCGATATCGAAAACCCG
G215R-fwd GCATCGTGTTGATTTTGACAAGATACTATGTGTCTTCTGAG
G215R-rev CTCAGAAGACACATAGTATCTTGTCAAAATCAACACGATGC
S219F-fwd GACAGGATACTATGTGTTTTCTGAGCTGTTTGGCG
S219F-rev CGCCAAACAGCTCAGAAAACACATAGTATCCTGTC
S219C-fwd GACAGGATACTATGTGTGTTCTGAGCTGTTTGGCGG
S219C-rev CCGCCAAACAGCTCAGAACACACATAGTATCCTGTC
G247R-fwd CTGGGGAGCGTCATTATCAGGACGTTTTTGTTTTATAAAG
G247R-rev CTTTATAAAACAAAAACGTCCTGATAATGACGCTCCCCAG
A301T-fwd CAACCGTTTCAACGCTCGCCATCGGGC
A301T-rev GCCCGATGGCGAGCGTTGAAACGGTTG
S316L-fwd GCTTACATCTCGTATTACTTGTCGGAAAAGACCGC
S316L-rev GCGGTCTTTTCCGACAAGTAATACGAGATGTAAGC
G381D-fwd GCAGGGCGATCCCGACAATATGCAGCTTG
G381D-rev CAAGCTGCATATTGTCGGGATCGCCCTGC
V426I-fwd GGACTCTGGTGTTATTAAAATAAAAAGCAAGCACGAGACG
V426I-rev CGTCTCGTGCTTGCTTTTTATTTTAATAACACCAGAGTCC
H430Y-fwd GGTGTTATTAAAGTAAAAAGCAAGTACGAGACGCAGCCATT
H430Y-rev AATGGCTGCGTCTCGTACTTGCTTTTTACTTTAATAACACC
G525D-fwd GCGCAAAAATCACTGTTTGATATGGTGATGTTCATCGTC
G525D-rev GACGATGAACATCACCATATCAAACAGTGATTTTTGCGC
G535E-fwd ATCGTCGGCTTCTTAGAGTTAACGTTCCTGATTACATC
G535E-rev GATGTAATCAGGAACGTTAACTCTAAGAAGCCGACGAT
S542L-fwd GGGTTAACGTTCCTGATTACATTAGGTTGTATCCTTTATT
TTAAAC
S542L-rev GTTTAAAATAAAGGATACAACCTAATGTAATCAGGAACG
TTAACCC
C544Y-fwd CGTTCCTGATTACATCAGGTTATATCCTTTATTTTAAACA
AATGGG
C544Y-rev CCCATTTGTTTAAAATAAAGGATATAACCTGATGTAATCA
GGAACG
M551I-fwd CCTTTATTTTAAACAAATAGGTGAAAGTGAAGATGAAAAA
CCGAGC
M551I-rev GCTCGGTTTTTCATCTTCACTTTCACCTATTTGTTTAAAAT
AAAGG
TABLE 2 (Continued)
Primer name Sequence (5=–3=)
L567P-fwd TACAATTTTAAGAAAACCCGGCTTTACGCAGGGCG
L567P-rev CGCCCTGCGTAAAGCCGGGTTTTCTTAAAATTGTA
G593D-fwd CATTCCGCTCGTTGTCGACCTCTTCCACAGTTAC
G593D-rev GTAACTGTGGAAGAGGTCGACAACGAGCGGAATG
G593C-fwd CATTCCGCTCGTTGTCTGCCTCTTCCACAGTTAC
G593C-rev GTAACTGTGGAAGAGGCAGACAACGAGCGGAATG
G609R-fwd CGGCTGGTTCTTATTCAGATCAGAGGTATGGGC
G609R-rev GCCCATACCTCTGATCTGAATAAGAACCAGCCG
M616I-fwd GAGGTATGGGCGCCTATAATTATGGTGATGGTG
M616I-rev CACCATCACCATAATTATAGGCGCCCATACCTC
V619 M-fwd GGGCGCCTATGATTATGATGATGGTGTTATATACTGC
V619 M-rev GCAGTATATAACACCATCATCATAATCATAGGCGCCC
T624I-fwd GGTGATGGTGTTATATATTGCGCTCTACTCCATTTTTGG
T624I-rev CCAAAAATGGAGTAGAGCGCAATATATAACACCATCACC
S628P-fwd GTTATATACTGCGCTCTACCCCATTTTTGGTTTTCTGTC
S628P-rev GACAGAAAACCAAAAATGGGGTAGAGCGCAGTATATAAC
a Restriction sites are underlined; nucleotides encoding the triple FLAG tag are shown in
italics.
b The introduced mutation is underlined.
Mutagenesis Analysis of BceAB
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pFK727 (BceB-FLAG3) was used. Cells were grown at 37°C in LB medium
supplemented with 0.2% of xylose to an OD600 of 1.0, collected by cen-
trifugation, and resuspended in lysis buffer (100 mM Tris-HCl [pH 8.0],
150 mM NaCl, 10% [wt/vol] glycerol, and 5 mM 2-mercaptoethanol).
Cells were lysed by sonication, and debris was removed by centrifugation
at 5,400 g for 15 min at 4°C. Membranes were pelleted by centrifugation
at 150,000  g for 45 min at 4°C and resuspended in lysis buffer. The
protein concentration of the membrane fractions was determined with a
BCA reagent kit (Pierce) according to the manufacturer’s protocol. Mem-
brane fractions (30 g protein) were separated on denaturing 12% poly-
acrylamide gels according to the method of Laemmli (25), blotted onto an
Immobilon-FL polyvinylidene difluoride (PVDF) membrane (Millipore),
and probed with rabbit anti-FLAG antibodies (Sigma) (1:2,000). Alexa
Fluor 680-conjugated goat anti-rabbit antibodies (Li-COR) (1:25,000)
were used as the secondary antibody. Hybridization of both antibodies
was carried out in 2.5% (wt/vol) skim milk powder–1 Tris-buffered
saline (TBS)– 0.2% (wt/vol) Tween 20. Infrared fluorescence signals were
quantified with an Odyssey infrared scanning system (Li-COR).
Bacterial two-hybrid assays. To test protein-protein interactions be-
tween BceB and BceS or between BceB and BceA, E. coli BTH101 was
cotransformed with pAS2505 or derived mutant constructs and either
pAS1803 or pAS1804. Of each transformation mixture, 10l was spotted
onto LB agar plates containing 0.5 mM isopropyl -D-1 thiogalactopyra-
noside (IPTG) and 40 g ml1 X-Gal, with selection for ampicillin and
kanamycin resistance. Plates were incubated at 30°C for 48 h. Formation
of blue colonies was scored as a positive interaction result.
RESULTS
Identification of signaling-defective derivatives of BceB. In or-
der to identify mutations that led to a loss of the signaling activity
of the BceAB transporter, a plasmid (pER703) containing only the
permease gene (bceB) under the control of the xylose-inducible
promoter Pxyl was chosen. In a previous study, this construct had
been described as leading to poor complementation of signaling in
a bceB-deleted strain of B. subtilis (10). However, a subsequent
more detailed characterization showed that the signaling activity
in this strain was in fact high at very low bacitracin concentrations:
it showed a maximal induction of the target promoter, PbceA, be-
tween 0.1 and 0.5 g ml1 bacitracin (data not shown), whereas
previous assays had been performed at 50 g ml1 bacitracin,
which is lethal to this strain and therefore led to the earlier obser-
vation of low signaling output (10). We attribute this phenotype
to very weak expression of bceB due to the poor ribosome binding
site of the gene, resulting in low levels of the transporter in the cell
and thus in increased bacitracin stress and associated signaling at
lower concentrations. This construct was ideally suited for the
identification of loss-of-function mutations, because screening
could be carried out at concentrations that are sublethal even for
strains with defects in bceAB (MIC  4 g ml1; see below and
Table 3).
Chemically mutagenized plasmid DNA of pER703 was used to
transform strain TMB301, which carries a deletion of bceB and a
PbceA-lacZ reporter construct (10). After growth on indicator
plates containing 0.5g ml1 bacitracin and X-Gal, colonies con-
taining functional copies of bceB were dark blue, while those car-
rying defective constructs were white. We screened approximately
20,000 colonies, leading to the identification of 33 clones with an
amino acid exchange causing a loss of signaling activity. Most
constructs carried only a single point mutation, and some ex-
changes were obtained in multiple independent clones (three
clones with A301T, two with M551I, and two with a mutation of
S219 to F or P, respectively), indicating nearly complete saturation
of the screen.
In total, 28 different amino acid exchanges were identified. A
striking first observation was an accumulation of mutations in the
C-terminal region (from position 523) of BceB, particularly in the
eighth and tenth transmembrane helices (Fig. 1). To further char-
acterize the obtained mutations, 26 amino acid exchanges were
reconstructed individually using site-directed mutagenesis of
plasmid pSG704. This construct contains the entire transporter
operon bceAB under the control of Pxyl and shows much stronger
complementation of both resistance and signaling activities in a
bceAB-deleted strain than pER703 (see below). Importantly, the
xylose-inducible promoter ensured equal bceAB expression levels
for all of the mutants, irrespective of their signaling activity. Two
mutations (T409I and S512L) could not be reconstructed despite
several attempts and were therefore not analyzed further. Addi-
tionally, the serine residue at position 219 was replaced not only by
Phe as in the original mutation but also by Cys to introduce a more
conserved change (-OH by -SH group; see below). All 26 ex-
changes are summarized in Table 3.
Resistance behavior of mutant derivatives. Because the iden-
tification of mutations was based on their loss of signaling activity,
it was first tested whether they were still able to confer bacitracin
resistance or whether both functions of the transporter were af-
fected. For this, the wild-type construct pSG704 and all derived
mutant constructs were introduced into strain TMB035 (bceAB::
Kan). The MIC of TMB035 was determined as 4 g ml1 bacitra-
cin and that of SGB170 (bceAB::Kan transformed with wild-type
pSG704) as 32g ml1. It should be noted that the parental strain
B. subtilisW168 has an MIC for bacitracin of 128g ml1 and that
pSG704 does not fully complement the deletion of bceAB. For the
purpose of discussing the obtained mutations, the reduced MIC of
TABLE 3 Summary of mutations analyzed in this study
Amino acid
exchangea
MIC
(g/ml)b Signaling phenotypec
Interaction
with BceSd
A75T 8–16 Altered sensitivity 
R83W 4–8 Altered sensitivity 
G215R 8–16 Low signal output 
S219F 4–8 Wild type like 
S219C 4 No activity ND
G247R 4 No activity ND
A301T 8–16 Low signal output 
S316L 4 Low signal output 
G525D 4–8 No activity 
G535E 4–8 Altered sensitivity 
S542L 8–16 Altered sensitivity 
L567P 32 Altered sensitivity ND
C544Y 8 No activity 
M551I 16 Low signal output 
G609R 4–8 Altered sensitivity ND
M616I 8–16 Wild type like 
V619M 8–16 Low signal output 
a The following mutations showed wild-type behavior: R9Q, V22M, A117T, V130I,
G381D, V426I, H430Y, G593D, T624I, and S628P.
b Data represent MIC of bacitracin. MICs between two values showed variable results
between biological triplicates; the MIC for a strain carrying the wild-type construct is 32
g/ml and for TMB035 (bceAB::Kan) is 4 g/ml.
c Categories of phenotypes as detailed in the text and shown in Fig. 2.
d As determined by bacterial two-hybrid assays (Fig. 4)., interaction;, no
interaction; ND, not determined.
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strain SGB170 is referred to as the “wild-type” resistance level
throughout this article.
The strains carrying mutated complementation constructs fell
into three groups of resistance phenotypes (Table 3). Seven mu-
tations caused a (nearly) complete loss of resistance, as seen by
MIC values of 4 or of 4 to 8 g ml1. Eight mutations retained a
partial ability to confer resistance, with the resulting strains dis-
playing MICs between 8 and 16 g ml1, and the remaining 11
mutations did not appear to affect resistance (MIC 32g ml1).
Mapping these different categories of phenotypes onto the pre-
dicted transmembrane topology of BceB did not reveal any obvi-
ous correlation between the position in the protein and the sever-
ity of the mutation’s effect, apart from the general clustering of
mutations in the C-terminal half of BceB as mentioned above
(Fig. 1A).
Signaling behavior ofmutant derivatives. For a detailed anal-
ysis of the signaling defects caused by the identified amino acid
exchanges, the wild-type plasmid pSG704 and mutated derivatives
FIG 1 Distribution of amino acid exchanges in BceB by effects on resistance and signaling. The position of each amino acid exchange in the predicted
transmembrane topology of BceB is marked by a star, and the exact exchange is given. Shading of stars is according to the effects of each mutation on bacitracin
detoxification (A) or activation of signal transduction (B). Exchanges resulting in wild-type behavior are not shown. Details on the observed phenotypes are given
in the text and Table 3. Topology prediction was carried out by MemBrain (30), and the results are displayed using TOPO2 (http://www.sacs.ucsf.edu/). The
cytoplasmic membrane is indicated by horizontal lines, and the orientation of the schematic is given on the left.
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were introduced into strain SGB079 that carries a deletion of
bceAB and a reporter construct of the target promoter PbceA fused
to luciferase. The strain harboring the wild-type construct showed
only low basal expression of the promoter in the absence of baci-
tracin (ca. 2 103 RLU OD1), which was induced 10-fold in the
presence of 3g ml1 of bacitracin. Addition of 10 or 30g ml1
bacitracin led to a strong upregulation of promoter activity, reach-
ing ca. 6 105 and 1 106 RLU OD1, respectively, within 45 min
postinduction (Fig. 2A, panel “WT-like”).
Analysis of the mutated constructs showed that their signaling
phenotypes could be classified into four different categories.
About half of the derived strains displayed behavior similar to that
of the wild type, with maximum induction occurring after addi-
tion of 30g ml1 bacitracin and reaching between 60% and 90%
of the maximal activity compared to the wild type (Fig. 2B, panel
“WT-like”). Six mutants also reached between 60% and 80% of
the maximal activity, and yet they responded most strongly to the
lowest concentration of 3 g ml1 bacitracin and had reduced
activities at 10 or 30g ml1 (Fig. 2, panels “Altered sensitivity”).
Most of these strains also had low MIC values, and we speculate
that this reduced ability to detoxify bacitracin may be the actual
cause of the signaling “defects”: poor efficiency in removing the
antibiotic would cause increased bacitracin stress at low concen-
trations, leading to an increase in signaling compared to the wild-
type level. At concentrations above the MIC (i.e., 10 or 30 g
ml1), growth inhibition and cell death would then cause an ap-
parent reduction in promoter activation. Apart from the changed
dose-response behavior, the overall output of this group of BceB
derivatives was high (ca. 80% of the wild-type level; Fig. 2), sug-
gesting that the signaling pathway itself was intact in these pro-
teins. The third category of mutants displayed overall low levels of
promoter induction, reaching only 20% to 30% of the wild-type
level. Their dose-response behavior differed between strains
(Fig. 2, panels “Low signal output”). The final group was com-
prised of four strains that were unable to induce expression of the
reporter construct (Fig. 2, panels “No activity”). The apparent
slight increase between 40 and 60 min postinduction is likely an
experimental artifact derived from normalizing luminescence val-
ues to OD600 values near zero, due to addition of lethal bacitracin
concentrations. A comparison of signaling phenotypes to bacitra-
cin resistance for each mutant is presented in Table 3.
To determine if there was a correlation between the position of
the mutated amino acid in the protein and the observed pheno-
type, all mutations with an effect on signaling were mapped onto
the predicted transmembrane topology of BceB (Fig. 1B). Those
mutations with a strong effect (categories “no activity” or “low
signal output”; black and gray stars in Fig. 1B) appeared to pre-
dominantly lie in the second half of the protein, particularly in the
transmembrane helices flanking the extracellular domain of BceB.
Of the 26 amino acid exchanges constructed, 10 displayed
wild-type behavior for both signaling and resistance activities.
These were either false-positive hits from the screen or had been
identified in plasmids containing multiple point mutations and
were not further characterized.
Comparison of BceB production levels. To enable interpreta-
tion of the observed effects caused by the mutations, it was first
important to test whether there were any differences in produc-
tion levels of the derived proteins. For this, the plasmid construct
used for the characterizations described above was modified to
contain a triple FLAG tag on the C terminus of BceB (pFK727),
which did not affect the activity of the protein (not shown). After
introduction of this plasmid into TMB035 (bceAB::Kan), a single
band could be detected in membrane fractions by anti-FLAG
Western blot analysis (Fig. 3). This band migrated at ca. 60 kDa,
which corresponds to the migration of BceB after expression and
purification from E. coli membranes (our own unpublished re-
sults). All mutations that caused a defect in at least one of the
activities tested as described above were then introduced into
pFK727 and expression levels compared to the wild-type con-
struct. With the exception of BceB carrying the G247R substitu-
tion, which was not detectable by Western blotting, all derivatives
of BceB were produced at the same level as the wild-type protein
(Fig. 3). Therefore, the observed phenotypes were direct effects of
the amino acid exchanges and cannot be explained by altered pro-
tein expression.
Protein-protein interactions between BceB and BceA or
BceS. Because the signaling pathway within Bce-like modules in-
volves both the transporter and the histidine kinase (10, 26) and
because the permeases and histidine kinases were shown to have
coevolved (9), direct interactions between the two proteins have
been proposed. The first experimental evidence for this was ob-
tained for a Bce-like system from S. aureus, using a bacterial two-
hybrid assay (15). In order to test these interactions within the Bce
module of B. subtilis, we fused BceB, BceS, and BceA to the T18
and T25 domains of bacterial adenylate cyclase (22) and tested
these constructs for interaction. The optimal combination for in-
teractions between the permease and ATPase components of the
transporter was found to be BceA-T18 (pUT18-BceA) with T25-
BceB (pKT25-BceB) (Fig. 4A and data not shown). Interaction
between BceB and BceS could also be shown, with the strongest
results obtained for T25-BceB paired with BceS-T18 (pUT18-
BceS) (Fig. 4B and data not shown).
Two replacements, R83W and M551I, that both affected sig-
naling and resistance are located in cytoplasmic loops of BceB
(Fig. 1). It was therefore conceivable that they affected the inter-
action between permease and ATPase of the transporter. While
there is no conservation in sequence or even location of the inter-
face between permease and ATPase among the different types of
ABC transporters, in all cases the interaction involves a small cy-
toplasmic alpha-helix of the permease (27, 28). Because the two
cytoplasmic loops harboring the amino acids 83 and 551, respec-
tively, possess predicted alpha-helical structures and are thus can-
didate regions for interaction, we introduced these two mutations
into the two-hybrid plasmid pKT25-BceB and tested the con-
structs against BceA-T18. No differences compared to the wild-
type constructs were observed (Fig. 4A), showing that the physical
interaction between BceB and BceA was not affected. However,
this does not exclude potential defects in the coupling of ATP
hydrolysis to transport.
We next introduced mutations that caused a signaling defect
into pKT25-BceB and tested for interaction with BceS. Again,
most constructs showed the same blue coloration of colonies as
seen with wild-type BceB, with the exception of G215R, which
produced white colonies and was thus no longer able to interact
with BceS (Fig. 4B). These results show that the majority of mu-
tations did not abolish the physical interaction between the trans-
porter and histidine kinase but rather affected signaling by more
subtle changes.
Genetic separability of signaling and resistance. Many of the
mutations identified in this study affect signaling and resistance to
Kallenberg et al.
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FIG 2 Signal transduction activities. (A) Time courses of promoter induction after addition of Zn2-bacitracin (Bac; concentrations are given in the key) in
strains harboring the PbceA-luxABCDE reporter construct pSDlux101. Bacitracin was added to exponentially growing cultures at time point 0 min, and lumi-
nescence (relative luminescence units, RLU) and cell growth (optical density at 600 nm, OD) were measured in 5-min intervals. Luminescence was normalized
to cell density and is expressed as RLU OD1. Example graphs for strains displaying the four observed categories of signaling phenotypes are shown [“WT-like,”
strain SGB082 carrying the wild-type sequence construct pSG704; “Altered sensitivity,” strain carrying pSG704(R83W); “Low signal output,” strain carrying
pSG704(A301T); “No activity,” strain carrying pSG704(C544Y)]. The arrows indicate the time (48 min postinduction) used to compare all mutated strains in
panel B. (B) Dose-response behavior of all analyzed strains at 48 min postinduction. The example strains also shown in panel A are indicated by asterisks.
Phenotype categories and labeling of symbols are as described for panel A. All data shown are the means standard errors of the means of the results determined
with four to six biological replicates.
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similar degrees; however, several amino acid replacements caused
drastic defects in only one of the two functions of the transporter,
pointing toward a genetic separability of the two traits.
The first group of such mutations includes A301T, M551I, and
V619M. In all three cases, signaling was reduced to ca. 10% to 20%
of the wild-type activity (Fig. 2B), and yet resistance was still main-
tained at a significant level (MIC  16 g ml1; Table 3). The
latter result shows that transport itself was affected only weakly by
the mutation and yet communication with the histidine kinase
was severely impaired. The mutations A301T and M551I were
isolated in three and two independent clones, respectively, during
our initial screen. A multiple sequence alignment of eight BceB
homologues shows that the position corresponding to A301 of
BceB is occupied by Ala or Thr in other transporters (Fig. 5). At
the position corresponding to M551, homologous transporters
possess other hydrophobic residues, such as Leu, Val, and Ile,
while position 619 contains small residues such as Val, Ala, and Ser
(Fig. 5). In all three of these strains, the amino acid exchanges are
therefore fairly conservative and thus are unlikely to cause major
structural changes within the transporter. This is consistent with
the unchanged ability of all three proteins to physically interact
with BceS in two-hybrid assays. It is tempting to speculate that
these amino acids are important for the communication between
transporter and histidine kinase. However, whether they are in-
volved in any direct interactions or are merely required to trans-
mit a signal (e.g., conformational change) within the transporter
to the interacting region(s) cannot be answered at this stage.
The opposite effect is observed with the replacement S219F:
while signaling was maintained at ca. 60% of the wild-type level
and the dose-response behavior was unaltered, this mutation
caused a complete loss of resistance (MIC  4 g ml1; Fig. 2B
and Table 3). In a previous study in S. aureus, it was shown that a
Bce-like transporter that was involved only in signaling and not in
resistance still required ATP hydrolysis and thus active transport
for signal transduction (14). This implies that B. subtilis BceB car-
rying the S219F mutation must still be able to transport bacitracin
to facilitate its nearly wild-type signaling behavior, which subse-
quently gives rise to the question of why it is unable to mediate
resistance. A possible explanation may be that the affinity for or
transport rate of bacitracin is too low to detoxify the antibiotic but
is still sufficient for signaling. The idea of a potential role of S219 in
substrate binding or translocation might be supported by its loca-
tion on the extracellular face of the cytoplasmic membrane (Fig. 1)
in the vicinity of the cellular target of bacitracin, undecaprenyl
pyrophosphate. Further studies on substrate binding and trans-
port will be required to answer this.
As mentioned above, in a second clone of our initial screen an
S219P mutation was identified, emphasizing the importance of
this position. The alignment of BceB homologues shows that this
position is commonly occupied by the small residue Ser or Ala
(Fig. 5), whereas both isolated mutations caused changes to bulky
amino acids. We therefore reconstructed the exchange with a re-
placement by Cys, which merely changes the hyroxyl side chain of
Ser to a sulfhydryl group. Surprisingly, this replacement led to a
complete loss of function (Table 3), possibly caused by oxidation
of the Cys side chain (although BceB does not contain any other
extracellular Cys residues that might form disulfide bridges with
Cys219), and again supports the idea of the functional importance
of position 219 in the transporter.
DISCUSSION
In this study, we chose a random mutagenesis approach to identify
residues and regions in the permease of the bacitracin transporter
BceAB that are involved in mediating resistance or signaling to the
histidine kinase. Fifteen such positions were found. Mapping
these amino acids onto the predicted transmembrane topology of
BceB showed an accumulation of mutations in the C-terminal half
of the protein, with six mutations clustering in transmembrane
helix VIII and the adjacent cytoplasmic loop (Fig. 1). This corre-
FIG 3 Production and membrane localization of BceB and its derivatives.
Single point mutations were generated in pFK727 and transformed into
TMB035. Membrane fractions (30 g) of strains carrying the wild-type se-
quence construct (WT) or derived mutated constructs were separated on a
12% denaturing polyacrylamide gel and analyzed by Western blotting using an
anti-FLAG antibody as described in Materials and Methods. The only detected
band in each lane migrated at a size of ca. 60 kDa, indicated by the arrows.
FIG 4 Protein-protein interactions of BceB and its derivatives. BceB and de-
rivatives were tested for interaction with BceA (A) and BceS (B). Single point
mutations were generated in pKT25-BceB and cotransformed with either
pUT18-BceA or pUT18-BceS as indicated into E. coli BTH101. Cells were
spotted onto LB plates containing X-Gal (40 g ml1), IPTG (0.5 mM), and
antibiotics for selection. Pictures were taken after 48 h of incubation at 30°C.
The blue colonies indicating positive results for interaction are depicted as
dark gray in the gray-scale image. The different intensities of colony coloration
within individual spots were a common observation that differed between
experiments and were most likely due to different levels of protein expression
in individual transformants.
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lation becomes even more pronounced when the degree of con-
servation of each position is considered: four of the five mutations
identified in the N-terminal half of the protein (up to transmem-
brane helix VI) affect highly conserved positions, i.e., A75, R83,
G215, and G247 (Fig. 5). It is therefore likely that these amino
acids have a structural role in the transporter and that no or little
functional information can be obtained from their characteriza-
tion. In particular, Gly residues within transmembrane helices,
such as G215 and G247, are often important for helix packing in
membrane proteins (29) and mutations are unlikely to be toler-
ated. Consistently, BceB carrying the exchange G247R was no lon-
ger produced (Fig. 3), and the mutation G215R abolished physical
interaction with BceS (Fig. 4).
In contrast, only one of the six mutations located in transmem-
brane helix VIII and the adjacent cytoplasmic loop affected a
highly conserved position, G525 (Fig. 5), and, again consistent
with a structural role of this Gly residue, this mutation led to a
complete loss of signaling and resistance activities (Table 3). The
remaining five positions, G535, S542, C544, M551, and L567, are
conserved only weakly or not at all (Fig. 5), and even drastic mu-
tations such as Gly to Asp or Glu still allowed at least partial activ-
ity of the transporter (Table 3). This region of BceB is therefore
clearly important for the specific functions rather than the global
structure of BceB. Because most of these mutations affect both
signaling and resistance, the low degree of conservation at these
positions may point toward a role either in substrate specificity or
FIG 5 Multiple sequence alignment of BceB and homologs. The amino acids of BceB that were changed during mutagenesis are indicated by arrowheads, and
their position numbers are given. The alignment was calculated using default settings of ClustalW implemented in BioEdit (31). Predicted transmembrane helices
of BceB are marked by gray lines below the alignment. The poorly conserved region of the extracellular domain (residues 320 to 510 [BceB numbering]) was
removed, as indicated by the diagonal black bars. Identical residues are shown as white letters on black fields and similar residues as black letters on a gray
background. The threshold conservation for shading was 70%. Names of proteins are given on the left. BceB and PsdB are from B. subtilis, ABC09 is from L. casei,
VraG, BraE, and VraE are from S. aureus, and EF2751 and EF2049 are from E. faecalis (see the text for references).
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in communication with BceS. It is, however, also conceivable that
the function of this transmembrane helix is the transmission of a
signal within the transporter. The location of transmembrane he-
lix VIII immediately adjacent to the large extracellular domain,
which was shown to constitute the determinant of substrate spec-
ificity in BceB-like transporters from S. aureus (14), might well
support the latter hypothesis, where extracellular binding of bac-
itracin may be communicated to the cytoplasmic face of the mem-
brane or even further toward the C-terminal end of the protein.
Interestingly, another cluster of mutations was found in the last
transmembrane helix, and these also affect positions of low se-
quence conservation (Fig. 5). However, as these mutations caused
differing defects in the transporter (Fig. 1 and Table 3), their func-
tional role remains unclear. There is as yet no clear indication of
where the interaction between BceB and BceS occurs. An extracel-
lular interaction appears unlikely, because BceS contains only
three predicted extracellular residues. Instead, an interaction ei-
ther within the membrane or between cytoplasmic domains might
be proposed. Such physical contacts could then transmit confor-
mational changes from the transporter to the histidine kinase,
causing changes in the autophosphorylation activities. Either po-
tential interaction site could explain the accumulation of muta-
tions in transmembrane helix VIII and the adjacent loop. How-
ever, with the current lack of in vitro data, such a model has to
remain speculation.
Despite its large size of over 200 amino acids, no mutation
could be identified in the extracellular domain of BceB. This is
consistent with the very low degree of sequence conservation of
this region across all BceB homologues identified to date, even
among transporters that share bacitracin as a substrate (9). Our
results therefore confirm the previously observed enormous free-
dom in sequence space of this domain, while it still retains full
activity.
Several mutations led to nearly complete loss of both activities.
These included all four mutations that were classified as “No ac-
tivity” in the signaling assays (Fig. 2), which all were also unable to
impart bacitracin resistance (MIC of 4 to 8 g ml1; Table 3). A
similar effect, albeit with 20% to 30% residual signaling activity,
was observed for mutations S316L and G215R (Fig. 2 and Table 3).
These mutations therefore appear to cause global defects in the
transporter. Of these, the mutation G215R presents an interesting
situation: the maximal promoter activation obtained in signaling
assays reached ca. 30% of wild-type levels (Fig. 2), and yet in bac-
terial two-hybrid assays this BceB derivative showed no interac-
tion with BceS (Fig. 4). As discussed above, exchange of the highly
conserved, membrane-located Gly residue for an Arg most likely
introduced structural changes in the transporter, and these ap-
peared to have strong effects on protein-protein interactions
within the Bce module. However, the significant signaling activity
observed suggests that while these interactions are sufficiently
weakened to give negative results in the two-hybrid assay, the
signal can still be passed to the histidine kinase. This is in contrast
to the remaining mutations that inhibit signaling but all still allow
a physical interaction in the two-hybrid analyses (Fig. 4 and Table
3). In these cases, the single amino acid exchange appears to be
insufficient to destroy the protein-protein interactions but may
rather affect the flow of information between BceB and BceS. Al-
ternatively, the effects of the mutation may have no direct connec-
tion to the signaling process itself but may rather affect the trans-
port process or transmission of conformational changes within
the transporter as discussed above.
In the course of earlier studies on BceAB-like transporters, sev-
eral systems could be identified that no longer possess the dual
functions for signaling and resistance but have become specialized
signaling or detoxification transporters. With the aim of identify-
ing specific residues for one or the other function, examples for all
three types of BceAB homologues were chosen for the multiple
sequence alignment shown in Fig. 5. BceB and PsdB ofB. subtilis as
well as ABC09 of L. casei belong to dual-function transporters (10,
11, 17). VraG and BraE of S. aureus are the permeases of trans-
porters that fulfill only a sensory function (14, 15), which is also
the case for EF2751 of Enterococcus faecalis (our own unpublished
results). As examples for transporters that mediate resistance but
no signaling, the permeases VraE of S. aureus (14) and EF2049 of
E. faecalis (our own unpublished data) were chosen. Comparison
of these sequences and the positions identified as important in our
mutagenesis screen did not reveal any patterns of sequence con-
servation that may be attributed to a particular role in either sig-
naling or resistance.
Nevertheless, we were able to show at least partial genetic sep-
arability of the two traits. Three exchanges (A301T, M551I, and
V619M) were associated with a strong reduction in signaling ac-
tivity but retained the ability to mediate significant bacitracin re-
sistance. One BceB derivative (S219F) displayed a complete loss of
resistance but was still capable of signaling (Fig. 2 and Table 3).
While the maximal signaling output was reduced to ca. 60% of the
wild-type level, it should be noted that the bacitracin concentra-
tion used (30g ml1), was well above the MIC value of the strain
(4 g ml1), which may lead to an underestimation of the actual
signaling activity of the transporter.
Furthermore, these results, particularly those from the three
mutations mentioned above (A301T, M551I, and V619M), help
to answer a long-asked question of the transporter’s role in signal-
ing. It has been proposed that BceAB might in fact function as an
importer rather than an exporter (10, 14). If this were the case, its
sole function in signaling might then be to transport bacitracin to
the cytoplasm where BceS might detect the antibiotic directly.
This hypothesis can now be refuted: BceAB carrying one of these
three mutations is still able to transport bacitracin at sufficient
rates to impart resistance. Thus, if it actually imports bacitracin,
resulting intracellular concentrations similar to those seen with
the wild type would have to be expected, and accordingly, if BceS
were a sensor of intracellular bacitracin, wild-type-like signaling
output should be observed. Yet only very low signaling is ob-
served, demonstrating that not BceS but the transporter itself,
irrespective of the direction of transport, is indeed the sensory
component of the module. Therefore, our findings not only show
that signaling and resistance are not strictly coupled functions of
BceB but also provide some valuable insights into the mechanism
of these unique resistance modules.
In summary, we here showed that mutations that affect specific
functions of BceAB are primarily found in the C-terminal half of
the permease, particularly in transmembrane helix VIII. This re-
gion will therefore be a primary target for future investigations
into the signaling and resistance mechanisms of this unusual
transporter. Our results further demonstrate that while signaling
and resistance are functionally interconnected, they are not
strictly coupled processes, even in a transporter like BceAB that is
capable of both activities.
Kallenberg et al.
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